Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 16, Number 10—October 2010

Research

Effectiveness of Personal Protective Equipment and Oseltamivir Prophylaxis during Avian Influenza A (H7N7) Epidemic, the Netherlands, 2003

Dennis E. te BeestComments to Author , Michiel van Boven, Marian E.H. Bos, Arjan Stegeman, and Marion P.G. Koopmans
Author affiliations: Author affiliations: Utrecht University, Utrecht, the Netherlands (D.E. te Beest, M.E.H. Bos, A. Stegeman); National Institute of Public Health and the Environment, Bilthoven, the Netherlands (D.E. te Beest, M. van Boven, M.P.G. Koopmans)

Main Article

Table 2

Risk for infection with avian influenza A (H7N7) with different levels of oseltamivir use, on the basis of combined conjunctivitis and serology-based case definition, the Netherlands, 2003*

Oseltamivir use Risk† (95% CI)
Not used 0.145 (0.078–0.233)
Not prescribed 0.161 (0.052–0.336)
Prescribed but not used during visit
0.138 (0.061–0.246)
Used 0.031 (0.008–0.073)
Prescribed and used consistently 0.015 (0.0008–0.0630)
Prescribed and used inconsistently 0.049 (0.004–0.157)
Prescribed and consistency of use unknown
0.068 (0.004–0.258)
Unknown 0.019 (0.001–0.080)
Prescribed but period of use unknown 0.020 (0.001–0.080)

*CI, confidence interval.
†Probability of infection per visit.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO